» Articles » PMID: 26474280

Peritumoral Cbl is a Strong Independent Prognostic Marker After Curative Resection of Hepatocellular Carcinoma

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Oct 17
PMID 26474280
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Growing evidences support the concept that peritumoral microenvironment gene expression is an important element for physicians to make an accurate prognosis. Nonetheless, the correlation between peritumoral ubiquitin ligases and the hepatocellular carcinoma (HCC) survival remains unclear till this present. The expression of intratumoral and peritumoral Casitas B-lineage Lymphoma (Cbl) and epidermal growth factor receptor (EGFR) in hepatocellular carcinomas (HCCs) followed by curative resection was assessed by tissue microarray-based immune-histochemistry in two independent cohorts (n = 352). Their respective prognostic values and other clinicopathologic factors were then evaluated. The peritumoral Cbl density, much higher than that in intratumoral tissue, was an independent prognostic factor for overall survival (P < 0.001) and time to recurrence (P < 0.001) of HCCs after curative resection. The hazard ratio were 1.587 and 1.689, respectively. However, there was no correlation between intratumoral Cbl and prognosis. The peritumoral Cbl was also associated with prognosis even in HCC subgroups with small tumor size, negative AFP, without microvascular invasion and negative HBeAg. After a thorough analysis pertaining to the key role of Cbl on ubiquitination and degradation of activated receptor tyrosine kinases, we eventually discovered the negative correlation between peritumoral Cbl and EGFR (P = 0.015). Furthermore, the combination of peritumoral Cbl and EGFR serves as a much stronger indicator to make an accurate prognosis, especially during early recurrence (P < 0.001). These findings suggest that low expression of peritumoral Cbl and EGFR were positively associated with tumor size, microvascular invasion and patients survival after hepatectomy, highlighting the key role of peritumoral liver milieu in HCC progression.

Citing Articles

The role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies.

Ren J, Lv L, Tao X, Zhai X, Chen X, Yu H Front Pharmacol. 2024; 15:1432545.

PMID: 39130630 PMC: 11310040. DOI: 10.3389/fphar.2024.1432545.


Regulation of apoptosis by ubiquitination in liver cancer.

Li Y, Zhu J, Yu Z, Zhai F, Li H, Jin X Am J Cancer Res. 2023; 13(10):4832-4871.

PMID: 37970337 PMC: 10636691.


MiR-486-5p Suppresses Proliferation and Migration of Hepatocellular Carcinoma Cells through Downregulation of the E3 Ubiquitin Ligase CBL.

He J, Xiao B, Li X, He Y, Li L, Sun Z Biomed Res Int. 2020; 2019:2732057.

PMID: 31976317 PMC: 6949685. DOI: 10.1155/2019/2732057.


Selected microRNA-192 mutant indicates association with several function genes in bovine cells.

Zi C, Zeng D, Zhou J, Dai J, Jiang L, Xue F Genes Genomics. 2018; 40(4):361-371.

PMID: 29892841 DOI: 10.1007/s13258-017-0635-3.


Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma.

Cui X, Lin Z, Chen Y, Mao X, Ni W, Liu J Mol Cell Biochem. 2016; 421(1-2):127-37.

PMID: 27573002 DOI: 10.1007/s11010-016-2793-z.


References
1.
Xu H, Zhu X, Zhuang P, Zhang J, Zhang W, Kong L . Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer. 2010; 128(7):1559-69. DOI: 10.1002/ijc.25492. View

2.
Sakr W, Haas G, Cassin B, Pontes J, Crissman J . The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993; 150(2 Pt 1):379-85. DOI: 10.1016/s0022-5347(17)35487-3. View

3.
Penengo L, Rubin C, Yarden Y, Gaudino G . c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene. 2003; 22(24):3669-79. DOI: 10.1038/sj.onc.1206585. View

4.
Grovdal L, Stang E, Sorkin A, Madshus I . Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 2004; 300(2):388-95. DOI: 10.1016/j.yexcr.2004.07.003. View

5.
Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi G, Ueno N . Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136(2):331-45. PMC: 3832208. DOI: 10.1007/s10549-012-2289-9. View